PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Fight for Sight to fund macular degeneration research

Fight for Sight, a UK-based eyesight research charity, has announced that it will funding researchers from the University of Manchester to investigate the genetic risk of the UK’s leading cause of blindness, age-related macular degeneration.

A team of researchers, led by Dr Rachel Taylor from the University of Manchester, say they will use a combination of cutting-edge technologies, including molecular “tools’” from bacteria – to analyse the impact of gene changes identified in families where there are multiple generations living with age-related macular degeneration.

Then, using genome editing the researchers plan to generate a bank of cells that carry the same DNA changes identified in patients who have macular changes under the age of 50 to model the condition.

The investigation will hopefully “enable us to better understand the role of gene changes in age-related macular degeneration and why this devastating condition can occur more in some families,” explained Dr Rachel Taylor.

She continued, “It could also allow for the development of genetic tests so that doctors can more accurately predict an individual’s likelihood of developing macular degeneration, estimate how it may affect their vision, and allow the development of a personalised treatment plan.”

Macular degeneration, also known as macular disease or age-related macular degeneration (AMD), causes loss of central vision as a result of damage to the macula – a tiny collection of light-sensitive cells found within the retina at the back of the eye.

Unfortunately, damage to the macula can’t be reversed, and it’s the most common cause of permanent and severe sight loss in the UK, affecting around 600,000 people.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026